Thomas S H, Shepherd S M, Allison E J
Department of Emergency Medicine, East Carolina University School of Medicine/University Medical Center of Eastern Carolina, Greenville, North Carolina 27858-4354.
J Emerg Med. 1993 Jan-Feb;11(1):83-9. doi: 10.1016/0736-4679(93)90012-v.
The use of thrombolytic agents for both coronary and noncoronary indications is a rapidly progressing field. There has been substantial debate over which disease processes ultimately benefit from the use of thrombolytic agents. In addition, many recent studies have focused on comparing different thrombolytic agents and dosing regimens in an attempt to gain optimal therapeutic benefit with minimal risk. This paper discusses the current status of thrombolytic therapy for coronary artery disease, pulmonary embolus, peripheral vascular thrombosis, and cerebrovascular infarction.
溶栓药物在冠状动脉和非冠状动脉适应症中的应用是一个快速发展的领域。关于哪些疾病过程最终能从溶栓药物的使用中获益，一直存在大量争论。此外，最近许多研究集中在比较不同的溶栓药物和给药方案，试图以最小的风险获得最佳治疗效果。本文讨论了冠状动脉疾病、肺栓塞、外周血管血栓形成和脑血管梗死的溶栓治疗现状。
